Sequoia Backs $200 Million Warhound Bet on Gene-Edited Military Canines

Warhound, a startup co-founded by Palmer Luckey, has raised $200 million to genetically modify dogs for military applications. Reports published on October 23, 2026, state that the company intends to use gene editing to improve the animals' ability to detect explosives and assist in protecting troops.

The funding round includes investment from Sequoia. Colossal Biosciences is reportedly providing technical support for the cloning and gene-editing processes. Luckey, who previously founded Oculus and Anduril Industries, is positioning the venture as a biotech effort to upgrade traditional military assets.

The company claims the enhanced canines will offer superior sensory capabilities compared to standard breeds. The specific genes targeted for modification were not detailed in the initial reports. Investors are betting that biological enhancements can provide a tactical advantage in combat environments where electronic sensors may fail.

The raise comes as other biotech firms pursue similar goals in the healthcare sector. On the same day, Moderna and Merck announced that their mRNA cancer vaccine reduced death rates by 42% in clinical trials. The study also showed a lower risk of melanoma recurrence among treated patients.

Separate research indicates that prime editing, a gene-editing technique, has reached its first human patient. This method rewrites DNA within liver cells. The progress marks a step forward for therapies that correct genetic errors rather than merely managing symptoms.

In cybersecurity, experts are assessing recently disclosed flaws in PHP. Although the vulnerabilities caused some websites to go offline, no successful attacks have been confirmed yet. Analysts say the bugs are harder to exploit than initially feared. Volunteer developer Ondřej Surý has been credited for creating critical patches to stabilize the software.

The launch of Warhound’s program coincides with ongoing debates about the role of technology in warfare. The $200 million investment signals a shift toward biological engineering in defense procurement. The company plans to use the capital to advance its research and development pipeline.